LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

Inicio・Lista de Acciones・Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Cerrado

SectorSalud

19.57 -1.66

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

19.32

Máximo

19.98

Métricas clave
By Trading Economics
Ingresos	-297M -81M
Ventas	-259M 200M
P/B Media del Sector	115 66.845
BPA	1.67
Margen de beneficio	-40.687
Empleados	733
EBITDA	-275M -47M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+57.93% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-197M 2.6B
Apertura anterior	21.23
Cierre anterior	19.57

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

79 / 351 Clasificación en Healthcare

Apellis Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

9 mar 2026, 18:13 UTC

Adquisiciones, fusiones, absorciones

Shell to Sell Jiffy Lube to Monomoy in $1.3 Billion Deal -- Update

9 mar 2026, 17:20 UTC

Noticias de Eventos Importantes

U.S. Ag Industry Calls for Government Intervention on Fertilizer Prices

9 mar 2026, 17:15 UTC

Adquisiciones, fusiones, absorciones

Shell to Sell Jiffy Lube and Premium Velocity to Monomoy for $1.3 Billion

10 mar 2026, 00:00 UTC

Noticias de Eventos Importantes

Why Iranian Regime Change Would Transform Global Energy Markets -- WSJ

9 mar 2026, 23:52 UTC

Charlas de Mercado

Gold Steady; May Be Supported by Dollar's Weakness -- Market Talk

9 mar 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Rise as Fears About Higher Energy Prices Ease -- Market Talk

9 mar 2026, 23:50 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

9 mar 2026, 23:46 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Correction to Crude Prices Market Talk on March 9

9 mar 2026, 23:42 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Fall Amid Developments That Could Help Supply -- Market Talk

9 mar 2026, 23:08 UTC

Noticias de Eventos Importantes

Front-Month WTI Futures Drop 7.9% to $87.29/bbl, ICE Data Show

9 mar 2026, 23:07 UTC

Noticias de Eventos Importantes

Front-Month WTI Futures Fall After Trump Says Iran War Will Be Over 'Very Soon'

9 mar 2026, 21:29 UTC

Adquisiciones, fusiones, absorciones

Fortescue Now Fully Owns Peru's Canariaco Copper Project

9 mar 2026, 21:28 UTC

Adquisiciones, fusiones, absorciones

Fortescue Completes Acquisition of Remaining Alta Copper Shares

9 mar 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 mar 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

9 mar 2026, 20:47 UTC

Noticias de Eventos Importantes

The 24 Hours When Oil Markets Went Wild -- WSJ

9 mar 2026, 20:33 UTC

Noticias de Eventos Importantes

Stock Market Today: Oil Slips, Stocks Bounce on Trump War-Progress Comments Headline -- WSJ

9 mar 2026, 20:14 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Moves Lower As Trump Says War Could End Soon -- Market Talk

9 mar 2026, 19:33 UTC

Noticias de Eventos Importantes

High Oil Prices Could Crimp Convenience Store Margins -- Barrons.com

9 mar 2026, 19:17 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Prospect of Added Supply From Oil Reserves Ease Inflation Fears -- Market Talk

9 mar 2026, 19:14 UTC

Charlas de Mercado

Oil Settles Off Highs As G7 Discusses Tapping Reserves -- Market Talk

9 mar 2026, 19:00 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

9 mar 2026, 18:23 UTC

Charlas de Mercado

Noticias de Eventos Importantes

BofA Drops Canada Rate-Cut Call on Higher Oil Prices -- Market Talk

9 mar 2026, 17:58 UTC

Adquisiciones, fusiones, absorciones

Shell to Sell Jiffy Lube to Monomoy in $1.3B Deal -- Update

9 mar 2026, 17:57 UTC

Adquisiciones, fusiones, absorciones

Activist Investors Target Food Companies as Growth Slows. Lamb Weston Is the Latest. -- Barrons.com

9 mar 2026, 17:41 UTC

Noticias de Eventos Importantes

U.S. and Western Allies Turn to Reserves to Counteract Gulf Oil Crisis -- WSJ

9 mar 2026, 17:41 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Reports of Saudi Production Shut-Ins Keep Bid in Crude -- Market Talk

9 mar 2026, 17:08 UTC

Charlas de Mercado

Canada Rate Outlook Shifts From Long Pause to Late 2026 Hike -- Market Talk

9 mar 2026, 17:04 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Global Forex and Fixed Income Roundup: Market Talk

9 mar 2026, 17:04 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Treasury Yields, Dollar Off Highs as G7 Tackles Oil Shock -- Market Talk

Comparación entre iguales

Cambio de precio

Apellis Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

57.93% repunte

Estimación a 12 meses

Media 31.57 USD 57.93%

Máximo 48 USD

Mínimo 18 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Apellis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

15 ratings

Comprar

Mantener

Vender

De acuerdo con 15 analistas que ofrecen calificaciones bursátiles a para Apellis Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

79 / 351 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.